Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression propionic patients, carriers, and controls

ABSTRACT: Gene expression in LCLs from PA patients, their parents, and HapMap sex and age match controls at low glucose (9 mg/dL) and normal glucose growth conditions.

ORGANISM(S): Homo sapiens

PROVIDER: GSE42816 | GEO | 2013/01/01

SECONDARY ACCESSION(S): PRJNA183488

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Gene expression propionic patients, carriers, and controls

Project description:Gene expression in LCLs from PA patients, their parents, and HapMap sex and age match controls at low glucose (9 mg/dL) and normal glucose growth conditions. 12 LCLs from Pa patients (coriell samples) 15 LCLs from parents of PA patient, 16 controls (HapMAp) who grown at low glucose (9mg/dL) and normal glucose for 24 hours. Then harvested for gene expression

2013-01-01 | E-GEOD-42816 | biostudies-arrayexpress

Effects of glucose exposures on gene expressions in HepG2 cells

Project description:SULT1E1, the enzyme that specifically and effectively sulfates estrogens to its inactive forms-sulfated estrogens has been found to be highly induced in high glucose (450 mg/dL) cultured human liver hepatocellular carcinoma HepG2 cells. To confirm the SULT1E1 transcription in response to glucose exposures and to investigate whether glucose signal may alter the other xenobiotic metabolizing enzyme transcripts in HepG2 cells, we have conducted whole genome microarray expression profiling as a platform to identify genes that may response to glucose exposures. HepG2 cells were exposed to low glucose (40 mg/dL) or high glucose (450 mg/dL) DMEM for 48 hours respectively. The xenobiotic metabolic enzyme transcripts such as SULTs, CYPs, UGTs and GSTs were significantly altered in response to glucose exposures.

2020-08-26 | GSE140867 | GEO

Proteins associated with RORalpha binding element on SULT1E1 gene

Project description:Estrogen sulfotransferase (SULT1E1) metabolically inactivates estrogen and SULT1E1 expression is tightly regulated by multiple nuclear receptors in cells. A series of biochemical techniques have clearly demonstrated that nuclear receptors HNF4alpha and phosphorylated RORalpha at Ser100 form as complexes binding to the SULT1E1 enhancer to activate gene transcription in response to a high glucose (450 mg/dL) signal. However, the kinase that mediates this phosphorylation at high glucose condition remain in mysterious. To identify these binding factors and possible kinases that mediate the phosphorylation on the SULT1E1 enhancer, the SULT1E1 enhancer was biotinylated and conjugated to magnetic beads, which were subsequently used to enrich the binding factors from low glucose (40 mg/dL) and high glucose (450 mg/dL) treated HepG2 cell nuclear extracts.

2020-08-26 | PXD016385 | Pride

Transcriptomic Profiling of Extracellular Vesicles Secreted by Fetal Neural Stem Cells Following Chronic Alcohol Exposure

Project description:To profile the transcriptome of samples by “sample type (EV vs. Cell)”, “sex (Female vs. Male)”, and “treatment (0 vs. 120 vs 320 mg / dL)”. We performed gene expression profiling analysis using data obtained from RNA-seq of 18 EV samples and 18 cell samples in different treatment groups and sex.

2023-04-19 | GSE214545 | GEO

Expression data from urinary exosome of diabetic and non-diabetic rats

Project description:We performed microarray miRNA expression profiling of diabetes induced rat via intraperitoneal (I.P) administration of streptozotocin (STZ). Rats were considered diabetic when their blood glucose exceeded 200 mg/dL (11 mmol/L).

2023-05-31 | GSE225393 | GEO

Expression data from human embryonic kidney cells (HEK293) cultivated in high and low glucose

Project description:Gene expression profiling of human embryonic kidney (HEK293) cells was performed to determine the effect of high and low glucose on gene expression. Microarrays were used to identify distinct classes of genes up-regulated in HEK293 cells during cultivation for 7 days in medium with physiological (low) glucose compared to high glucose. Human embryonic kidney cells (HEK293) were cultivated for 7 days in commercially available DMEM (supplemented with 10 % FCS) containing high glucose (450 mg/dl) or low glucose (100 mg/dl). Cells were harvested, total RNA was extracted and microarray gene expression profiling was performed to compare differential gene expression between low and high glucose conditions. Two biological replicates for each condition were made (high glucose: HEK-high-gluc-1 and HEK-high-gluc-2; and low glucose: HEK-low-gluc-1 and HEK-low-gluc-2).

2009-04-08 | E-GEOD-15575 | biostudies-arrayexpress

Genome-wide baseline microRNA expression quantification in HapMap phase I CEU and YRI samples

Project description:Baseline microRNA (miRNA) expression was evaluated in 107 HapMap lymphoblastoid cell lines (LCLs; 53 CEU and 54 YRI) using Exiqon miRCURY LNA arrays v10.0 (Exiqon array).

2012-07-29 | GSE34406 | GEO

Genome-wide baseline microRNA expression quantification in HapMap phase I CEU and YRI samples

Project description:Baseline microRNA (miRNA) expression was evaluated in 107 HapMap lymphoblastoid cell lines (LCLs; 53 CEU and 54 YRI) using Exiqon miRCURY LNA arrays v10.0 (Exiqon array). Total RNA from each of the 107 HapMap sample was labeled and hybridized onto an Exiqon array

2012-07-28 | E-GEOD-34406 | biostudies-arrayexpress

miRNA expression in healthy carriers of heterozygous BRCA1 mutation and healthy WT controls

Project description:In order to investigate whether carriers of BRCA1 heterozygous mutation show altered miRNA expression profiles, we established a panel of lymphoblastoid cell lines (LCLs) harboring either mutated or WT BRCA1 (control) and investigated their miRNA expression profiles. We were especially interested whether we find differences in miRNA expression between carriers of missense versus truncating mutation in BRCA1 gene. We evaluated the miRNA expression in a panel of 21 non-treated lymphoblastoid cell lines (LCLs). Among them, 6 LCLs with WT BRCA1, 5 LCLs carrying missense mutation in BRCA1, and 10 LCLs harboring truncating mutation in BRCA1 were included in this study.

2015-12-31 | E-GEOD-60444 | biostudies-arrayexpress

Transcriptomic characterization of the diabetic retinal response to chronic insulin treatment

Project description:The aim of this study was to identify alterations associated with diabetes-induced functional dysregulation of the retina and the effects of chronic insulin therapy. Transcriptional profiling through microarray analysis was analyzed to find mRNA targets of interest in diabetic samples, as well as in the insulin treated group. Verification of targets shown to be unrecovered in the insulin group was validated. Diabetes was induced in Sprague-Dawley male rats (Charles River Laboratories, Wilmington, MA) by intraperitoneal injection of 65 mg/kg streptozotocin (STZ)(Sigma-Aldrich, St. Louis, MO) in 10mM sodium citrate pH 4.5 vehicle. Control rats were injected with an equal dose of vehicle only. Rats had free access to food and water, and were maintained on a 12 hour light/dark cycle. Blood glucose level and body weight were measured 6 days post-STZ or vehicle injection, and biweekly throughout the experiment. Only rats with blood glucose levels >250 mg/dL at the time of the original test and throughout the experiment were included in the diabetic groups. The insulin treatment group received one 26mg subcutaneous pellet (LinShin Canada, Scarborough, Canada) delivered via trocar 6 weeks post-STZ injection. An additional 26 mg implant was introduced when body weight exceeded 300 g or when midday non-fasting blood glucose exceeded 250 mg/dL. At the time of retina harvest, rats were given a lethal dose of pentobarbital, 100 mg/kg, (Ovation Pharmaceuticals Inc., Deerfield, IL) by intraperitoneal injection and sacrificed by decapitation. Retinas were rapidly excised snap- frozen in liquid nitrogen for subsequent experimentation.

2011-05-23 | E-GEOD-24423 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data